


1/19

**FIG. 1**

2/19




FIG. 2

3/19




FIG. 3

4/19




FIG. 4

5/19

cluster 1




FIG. 5A

6/19

cluster 2





FIG. 5B

7/19

cluster 3**FIG. 5C**




FIG. 6

9/19




FIG. 7A




FIG. 7B




FIG. 7C

Human Whole Blood--Donor 528
 α TL1A Antibodies Plate 1




FIG. 8A

Human Whole Blood--Donor 528
 α TL1A Antibodies Plate 2




FIG. 8B




FIG. 9A




FIG. 9B




FIG. 9C

CDx performance against TL1A ex vivo production assay		Prometheus 360 Data Science Platform	
% of CDx+ subjects that are TL1A high producers (PPV)			86%
% of TL1A low producers that are CDx- (specificity)			90%
% of cohorts that is CDx+			32%
Enrichment of TL1A high producers in CDx+ subjects			4.6x

FIG. 10





FIG. 11A



Q4W = every 4 weeks; ® = Randomization